A compound of Formula: wherein: R 1 is -C OR 15 or -C NR 10 R 11; R 2 is H, halogen, C 1-6 alkyl, or C 1-6 haloalkyl; R 3 is A is N or C; X is -O-, -N(R 16)-, or -CH 2 N(R 16)CH 2 -; Y is -CH 2 - or -C -; Z is -S-, -O-, or -N(R 18)-; R 4 is H, halogen, -OR 7, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, -C NR 8 R 9, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -C 1-6 alkyl-C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl, wherein C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -C 1-6 alkyl-C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl are optionally substituted with 1 or 2 R 14; R 5 is H, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, or phenyl; R 6 is H, halogen or C 1-6 alkyl; R 7 is H, C 1-6 alkyl, C 1-6 haloalkyl, -C 1-6 alkyl-OH, C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl, wherein C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl are optionally substituted with 1 or 2 R 14; each R 8 and each R 9 are independently selected from H and C 1-6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring; R 10 and R 11 are each independently H or C 1-6 alkyl; R 12 is H, halogen, or C 1-6 alkyl; R 13 is H or C 1-6 alkyl; each R 14 is independently selected from halogen, -OH, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, -C 1-6 alkyl-OH, C 3-8 cycloalkyl, -C OH, -C NR 8 R 9, -SO 2 -C 1-6 alkyl, and -N(R 17)C -C 1-6 alkyl; R 15 is H or C 1-6 alkyl; R 16 is H, C 1-6 alkyl, -C -C 1-6 alkyl, -C 1-6 alkyl-OH, or -CH 2 CO 2 H; R 17 is H or C 1-6 alkyl; R 18 is H or C 1-6 alkyl; v is 0 or 1; n is 0 or 1; m is 0 or 1; p is 0, 1, or 2; and q is 0, 1 or 2; or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof. R 1 is -C OR 15 or -C NR 10 R 11; R 2 is H, halogen, C 1-6 alkyl, or C 1-6 haloalkyl; R 3 is A is N or C; X is -O-, -N(R 16)-, or -CH 2 N(R 16)CH 2 -; Y is -CH 2 - or -C -; Z is -S-, -O-, or -N(R 18)-; R 4 is H, halogen, -OR 7, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, -C NR 8 R 9, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -C 1-6 alkyl-C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl, wherein C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -C 1-6 alkyl-C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl are optionally substituted with 1 or 2 R 14; R 5 is H, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, or phenyl; R 6 is H, halogen or C 1-6 alkyl; R 7 is H, C 1-6 alkyl, C 1-6 haloalkyl, -C 1-6 alkyl-OH, C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl, wherein C 2-9 heterocycloalkyl, C 6-10 aryl, or C 1-9 heteroaryl are optionally substituted with 1 or 2 R 14; each R 8 and each R 9 are independently selected from H and C 1-6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring; R 10 and R 11 are each independently H or C 1-6 alkyl; R 12 is H, halogen, or C 1-6 alkyl; R 13 is H or C 1-6 alkyl; each R 14 is independently selected from halogen, -OH, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, -C 1-6 alkyl-OH, C 3-8 cycloalkyl, -C OH, -C NR 8 R 9, -SO 2 -C 1-6 alkyl, and -N(R 17)C -C 1-6 alkyl; R 15 is H or C 1-6 alkyl; R 16 is H, C 1-6 alkyl, -C -C 1-6 alkyl, -C 1-6 alkyl-OH, or -CH 2 CO 2 H; R 17 is H or C 1-6 alkyl; R 18 is H or C 1-6 alkyl; v is 0 or 1; n is 0 or 1; m is 0 or 1; p is 0, 1, or 2; and q is 0, 1 or 2; or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.